Search results

Articles (5)

Journals (0)

1-5 of 5 results for Immune Checkpoint Inhibitors (210)

Sort by:

Relevance

Select all

Sort by:

Relevance

Available accessResearch articleFirst published 2026

Correlation between lymphocyte counts and PD-L1 immune-related adverse events

Zachary Sawyer, Mark Sorial, Justin C Liauw

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2025

Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm,Multi-Centre Phase II Clinical Study

Junzhu Xu, Mi Meng, Sisi He [...]

Technology in Cancer Research & Treatment

Open accessResearch articleFirst published 2022

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study

Guangjian Yang, Yaning Yang, Runze Liu [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published October, 2020

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

Qiong Lyu, Anqi Lin, Manming Cao [...]

Cancer Control

Available accessResearch articleFirst published July, 2026

Reporting on Adverse Clinical Events

Clin-Alert

Search results

Articles (5)

Journals (0)

1-5 of 5 results for Immune Checkpoint Inhibitors (210)

Sort by:

Relevance

Select all

Sort by:

Relevance

Available accessResearch articleFirst published 2026

Correlation between lymphocyte counts and PD-L1 immune-related adverse events

Zachary Sawyer, Mark Sorial, Justin C Liauw

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2025

Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm,Multi-Centre Phase II Clinical Study

Junzhu Xu, Mi Meng, Sisi He [...]

Technology in Cancer Research & Treatment

Open accessResearch articleFirst published 2022

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study

Guangjian Yang, Yaning Yang, Runze Liu [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published October, 2020

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

Qiong Lyu, Anqi Lin, Manming Cao [...]

Cancer Control

Available accessResearch articleFirst published July, 2026

Reporting on Adverse Clinical Events

Clin-Alert